CLOV vs SUPN: Which Stock Is the Better Buy?
Clover Health Investments, Corp. and Supernus Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CLOV vs SUPN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Clover Health Investments, Corp. (CLOV) | Supernus Pharmaceuticals, Inc. (SUPN) | |
|---|---|---|
| Market cap | $2.6B | $2.6B |
| Revenue (latest FY) | $1.92B | $718.95M |
| Net income (latest FY) | $-85.55M | $-38.55M |
| Revenue growth (5y CAGR) | 23.4% | 6.7% |
| Net margin | -4.4% | -5.4% |
| Return on equity | -27.7% | -3.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 9 |
| Positive free cash flow | No | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full CLOV vs SUPN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CLOV's full financials → Open SUPN's full financials →More comparisons
Frequently asked questions
Which is bigger, CLOV or SUPN?
Supernus Pharmaceuticals, Inc. is larger by market capitalization — $2.6B versus $2.6B.
Which grows faster, CLOV or SUPN?
Over the last five fiscal years, Clover Health Investments, Corp. grew revenue faster — 23.4%/yr versus 6.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
CLOV fundamentals → · SUPN fundamentals → · All 1,500+ companies → · Free screener →